Novo Nordisk’s Hemophilia Breakthrough Fails to Distract From Canadian Generic Blow

Novo Nordisk's stock slides 41% as Canada approves first generic Ozempic, while promising hemophilia data fails to lift investor sentiment ahead of Q1 earnings.

A 99% reduction in bleeding events for hemophilia patients would normally be the kind of headline that sends a stock soaring. For Novo Nordisk, it barely registered. The Danish drugmaker’s shares closed at €34.55 on Wednesday, nursing a 41% decline over the past twelve months, as investors fixated on a far more immediate threat: the first generic version of Ozempic has just been approved in a G7 country.

Canada’s health regulator has given the green light to Dr. Reddy’s Laboratories for a semaglutide injection, marking the first time a copycat version of Novo Nordisk’s blockbuster diabetes drug has reached a major Western market. The patent on the active ingredient expired there at the start of January. The approval currently covers diabetes treatment only, not the weight-loss drug Wegovy, but the pricing implications are stark. Under Canadian guidelines, a single generic can push the price down to 75% of the original. Once three copies hit the market, that figure plummets to roughly 35%. Eight more applications are already sitting with regulators, and Sandoz has flagged a June launch for its own version.

Analysts are watching Canada as a potential bellwether. Evan Seigerman of BMO Capital Markets describes the development as a purely local headwind for now, pointing to the strong patent protections that shield the US market. India already approved its first semaglutide copies in March, prompting Novo Nordisk to slash prices there. The worry is that Canada could become a template for other developed economies.

The generic threat arrives as the company’s early dominance in the weight-loss injection market comes under sustained assault. Eli Lilly has been eating into market share with Mounjaro and Zepbound at a rapid clip. The stock’s technical picture reinforces the bearish mood: the relative strength index sits at 24.9, deep in oversold territory.

Amid the gloom, Novo Nordisk did deliver a genuine scientific win. Phase 3 data for denecimig, its experimental hemophilia A treatment, showed that a monthly dose cut bleeding episodes by 99% compared with no prophylaxis. Against existing preventive therapies, the reduction was still a robust 43%. The company filed for US approval last September, and the broader rare-disease space is heating up — Chiesi Group just snapped up specialist KalVista for $1.9 billion on Wednesday.

The market, however, has other priorities. A new daily weight-loss pill from a major competitor recently won FDA approval in the US, adding another layer of pressure. Novo Nordisk’s share buyback program, worth up to 15 billion Danish kroner, is providing some floor, but it has not been enough to reverse the slide.

All eyes now turn to May 6, when the company reports first-quarter earnings. Analysts are looking for earnings per share of $0.87. A few days later, on May 12, the European Congress on Obesity in Istanbul will see Novo Nordisk present fresh clinical data, including cardiovascular outcomes and women’s health results, as management tries to broaden Wegovy’s medical profile. Whether that will be enough to shift the narrative remains an open question.